Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 18 to 75 years (at screening for Cohort 1 and 2)~* UC confirmed on endoscopy~* Moderately to severely active UC (May score 6-12)~* Currently receiving treatment with aminosalisylate, prednisone, or budesonide~* Can be receiving azathioprine, mercaptopurine, or methotrexate, but treatment will be stopped prior to randomization~Exclusion Criteria:~* Have severe extensive colitis as evidence by:~* Physician judgment that the patient is likely to require colectomy or ileostomy within 12 weeks of baseline.~* Current or recent (within 3 months) evidence of fulminant colitis, toxic megacolon, or bowel perforation.~* Diagnosis of CD, indeterminate colitis, or the presence of fistula consistent with CD or microscopic colitis, radiation colitis, or ischemic colitis~* Clinically relevant cardiovascular conditions or other relevant diseases that could impact the implementation or interpretation of the trial, or put the patient at risk~* History of uveitis or unknown macular edema~* Pregnancy, lactation, or a positive serum β-human chorionic gonadotropin (β-hCG) measured during screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- RPC1063 (Ozanimod) (Type: EXPERIMENTAL): 1mg, daily oral administration during Induction and Maintenance periods.
- Placebo (Type: PLACEBO_COMPARATOR): Daily oral administration during Induction and Maintenance periods.

Based on this trial design, predict the completion outcome and termination type (if applicable).